2023 World Conference on Lung Cancer (Posters)-EP07.05. Prognostic Factors in Non-Small-Cell Lung Cancer Treated with Chemoimmunotherapy or Chemotherapy: A Real-World Data Study

EP07.05. Prognostic Factors in Non-Small-Cell Lung Cancer Treated with Chemoimmunotherapy or Chemotherapy: A Real-World Data Study - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to determine the prognostic factors in patients with non-small cell lung cancer (NSCLC) treated with chemotherapy (CT) or chemoimmunotherapy (Chemo-IO). The researchers analyzed real-world data from the AACR Project GENIE BPC NSCLC v2.0 dataset, which included 536 patients diagnosed with stage I-III NSCLC who received either CT or Chemo-IO regimens. The prognostic factors evaluated were age, sex, stage, and histopathology subtype.<br /><br />The results showed that age did not have a significant impact on overall survival (OS) in either the CT or Chemo-IO groups. However, survival was better among females compared to males in both groups. Adenocarcinoma histopathology subtype had superior OS rates compared to squamous cell carcinoma and other subtypes in patients who received CT or Chemo-IO. <br /><br />Additionally, earlier disease stages had more favorable survival compared to stage III in both treatment groups. The survival rates were comparable between the CT and Chemo-IO groups in these subgroups of patients. <br /><br />Overall, the study demonstrates that the OS benefit from CT or Chemo-IO is influenced by patient sex, histopathology subtype, and tumor stage, but not age. These findings suggest that personalized treatment strategies should be considered in clinical practice and future guidelines for NSCLC.

Asset Subtitle

Ayah Bani Mostafa

Meta Tag

Speaker Ayah Bani Mostafa

Topic Early-Stage NSCLC: Pushing the Boundaries

Keywords

prognostic factors

non-small cell lung cancer

chemotherapy

chemoimmunotherapy

real-world data

age

sex

stage

histopathology subtype

overall survival